Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

• 1. Overview of Pancreatic Cancer Biology2. Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender3. EMT Contributes to Chemoresistance in Pancreatic Cancer4. Pancreatic Cancer Resistance to Gemcitabine5. Pancreatic Cancer and Possible Therapeutic Options6. Curcumin and Genistein Enhances the Sensitivity of Pancreatic Cancer to Chemotherapy7. Terpenoids as Potential Targeted Therapeutics of Pancreatic Cancer: Current Advances and Future Directions8. Small Molecules and Pancreatic Cancer Trials and Troubles9. Targeting the Epigenome as a Therapeutic Strategy for Pancreatic Tumors - DNA and Histone Modifying Enzymes10. Are Nanocarriers Effective for the Diagnosis and Treatment of Pancreatic Cancer?11. Molecular Markers for Treatment Response and Toxicity of Gemcitabine